Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis, Bowen’s Disease, and Squamous Cell Carcinoma: A Systematic Review
Journal of Cutaneous Medicine and Surgery · 2024
DOI: 10.1177/12034754241256347 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Cutaneous Medicine and Surgery, 2024. Verfasst von Adam H Lapidus und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Alfred Health, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Fluorouracil, Calcitriol, Bowen's Disease, Keratosis, Actinic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Background/Objectives: Actinic keratoses (AK) are premalignant skin lesions caused by chronic sun exposure, topically managed by 5-fluorouracil (5-FU), diclofenac 3% gel, and imiquimod. Despite their effectiveness, long treatment duration and severe adverse local skin reactions have limited patient concordance. Calcipotriol has recently been used as a combination agent for existing topical AK treatments. A systematic review was performed to determine the clinical efficacy of 5-FU and calcipotriol for the treatment of AK, Bowen’s disease, and squamous cell carcinoma (SCC).
Methods
A systematic literature search was conducted on Medline, Embase, and Cochrane Library. Among the 84 records screened, 12 were retrieved for full-text review and 8 were included in the final analysis.
Results
Among the 8 studies, there were 214 control patients and 288 patients who received the intervention. The combination 5% 5-FU with calcipotriol resulted in a significant reduction in the number of AKs on the face, scalp, right upper extremity, and left upper extremity for all sites at 8 weeks ( P < .0001). No significant difference in SCC incidence was observed at 1 or 2 years, but there was a significant reduction observed at 3 years for SCC on face and scalp. No study assessed the combination for Bowen’s disease.
Conclusions
Combination 5% 5-FU with calcipotriol is an effective treatment for Aks; however, future trials may consider longer treatment and follow-up periods for the treatment and prevention of AK, SCC in situ, and SCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Alfred Health, Melbourne, VIC, Australia.
- Monash School of Medicine, Monash University, Melbourne, VIC, Australia.
- Department of Medicine, Central Clinical School, Monash University, Melbourne, VIC, Australia.
ORCID-Profile: Adam H Lapidus, Zhao Feng Liu
Zitieren
APA
Lapidus, A. H., Lee, S., Liu, Z. F., Smithson, S., Chew, C. Y., & Gin, D. (2024). Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis, Bowen’s Disease, and Squamous Cell Carcinoma: A Systematic Review. Journal of Cutaneous Medicine and Surgery. https://doi.org/10.1177/12034754241256347
Vancouver
Lapidus AH, Lee S, Liu ZF, Smithson S, Chew CY, Gin D. Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis, Bowen’s Disease, and Squamous Cell Carcinoma: A Systematic Review. Journal of Cutaneous Medicine and Surgery. 2024. doi:10.1177/12034754241256347
BibTeX
@article{Lapidus2024,
author = {Lapidus, Adam H and Lee, Sangho and Liu, Zhao Feng and Smithson, Sarah and Chew, Christopher Y and Gin, Douglas},
title = {Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis, Bowen’s Disease, and Squamous Cell Carcinoma: A Systematic Review},
journal = {Journal of Cutaneous Medicine and Surgery},
year = {2024},
doi = {10.1177/12034754241256347}
}
EUVIMED